|
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its...
|
|
|
Pivotal Trial Results For Motavizumab Published In Current Issue Of 'Pediatrics'
Respiratory / Asthma News Main Category: Respiratory / Asthma Also Included In: Infectious Diseases / Bacteria / Viruses; Pediatrics / Children's Health; Clinical Trials / Drug Trials email to a friend printer friendly view / write opinions Current Article...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of...
|
|
|
Clinical results of MedImmune's pivotal trial for motavizumab published
MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics: Official Journal of the American Academy of...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Companies mentioned in this article: MedImmune GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GA_googleFillSlot("Press336"); GA_googleFillSlot("Press160"); GAITHERSBURG, Md., Jan.29 -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of Pediatrics
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics' / Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics' / Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
GAITHERSBURG, Md., Jan.29 /PRNewswire/ -- MedImmune today announced that clinical results of its pivotal multinational, randomized, double-masked trial for motavizumab have been published in the current issue of the peer-reviewed publication, Pediatrics:...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
|
|
Pivotal Trial Results for Motavizumab Published in Current Issue of 'Pediatrics'
Phase 3 Pivotal Trial Demonstrated 26 Percent Relative Reduction in RSV Hospitalization; 50 Percent Relative Reduction in Incidence of RSV Outpatient Visits PR Newswire GAITHERSBURG, Md., Jan.29 GAITHERSBURG, Md., Jan. 29 /PRNewswire/ -- MedImmune today...
|
